GOSH statement on new personalised therapy for children with cancer
5 Sep 2018, 3:56 p.m.
Professor Persis Amrolia, Consultant in Bone Marrow Transplant at Great Ormond Street Hospital (GOSH), says:
“GOSH welcomes the exciting announcement that for children with Acute Lymphoblastic Leukaemia (ALL), CAR-T cell therapy will be made available on the NHS.
“This is a landmark moment in the treatment of childhood cancer in the UK. GOSH has been at the forefront of cutting edge personalised CAR-T therapy treatment for a number of years developing similar CAR-T therapies for children with ALL. Since 2012, we have treated over 25 patients from all over the UK with CAR-T therapies. In 2015, we treated the first patient worldwide with gene edited “universal” CAR-T cells. We are continuing to work on improving CAR-T cell therapy including using “next generation” CAR-T cells to further reduce the chance of relapse.
“We believe that personalised cell therapy treatments, which allow us to tailor treatments to individual patients, can be the silver bullet, offering a real chance of success for children who have run out of all other options.”
Consolidation of genomic testing improves care for children with cancer at GOSH
Doctors at Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) have started using a new service available as part of the North Thames Genomics Laboratory Hub (NTGLH) laboratory service to help better diagnose and manage childhood cancers
Learning from patients and families during a pandemic
Researchers have worked with a patient support group to better understand the wide range of parenting experiences during the pandemic.
Helping parents find answers after miscarriage
A team at GOSH have developed a non-invasive imaging technique for the post-mortem imaging of babies who are miscarried or stillborn.